Innovent Biologics and Sanegene Bio USA have entered a collaboration to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen (AGT) for hypertension treatment. SGB-3908, an IND-enabling stage siRNA drug, uses Sanegene Bio's LEAD (Ligand and Enhancer Assisted Delivery) platform. Both companies will jointly develop SGB-3908, and Innovent gains an exclusive option for future development, manufacturing, and commercialization rights. After exercising its option, Innovent will pay subsequent milestone payments and tiered royalties. The collaboration combines Sanegene Bio's RNA technology strength with Innovent's clinical development experience, aiming to accelerate SGB-3908's development for early benefits to hypertension patients. Hypertension affects over 1 billion people globally, and siRNA drugs like SGB-3908 present a potential long-term, compliance-friendly solution compared to traditional anti-hypertension treatments.